A*STAR, Oxford Biodynamics Partner On Stem Cell Research
Tech & Pharma
May 13, 2013
A*STAR and Oxford Biodynamics have agreed to collaborate on a project to identify epigenetic signatures in stem cells.
AsianScientist (May 13, 2013) – The Genome Institute of Singapore (GIS) from the Agency for Science, Technology and Research (A*STAR) and the UK-based Oxford Biodynamics (OBD) have agreed to collaborate on a project to identify epigenetic signatures in stem cells.
The research will use OBD’s proprietary EpiSwitch biomarker discovery platform which can be used to differentiate or confirm the epigenetic footprint of induced pluripotent stem cells (IPSCs), embryonic stem cells (EC-ESCs), or progenitor cells from representative cell lines.
In their first and immediate application, EpiSwitch biomarkers will provide a quick and efficient tool to monitor the quality and safety of IPSCs.
Epigenetic regulation in human cells is responsible for a large spectrum of inheritable, programmed changes in gene activities and the biochemical properties of the cells.
Monitoring highly specific epigenetic biomarkers, called chromosome conformation signatures, which define and control key aspects of epigenetic and gene regulation, is thus important for the correct assessment of its properties, functions and any signs of pathologies or abnormalities in human cells.
“We are delighted to be collaborating with GIS. GIS is one of the leading influences worldwide in the development of stem cell technology. Singapore’s focus on adoption of new technologies, like EpiSwitch, has been instrumental in translation of latest epigenetic scientific advances into practical industrial applications in health-care and drug development,” said Oxford Biodynamics CEO, Christian Hoyer Millar.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.